| Value | ₹62.00 Cr |
|---|
BSE filing, NSE: SENORES. Summary written from the filing by ALFA Finder's alert engine.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,324.30
- Market cap
- ₹6,099 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 48.3×Sector 46.1×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Board Meeting Date
Senores Pharmaceuticals has scheduled a board meeting for October 29, 2026, to approve its unaudited financial results for the quarter and half-year ended September 30, 2026.
Senores Pharmaceuticals Annual General Meeting
Senores Pharmaceuticals Limited has issued a Postal Ballot Notice seeking shareholder approval for the re-appointment of its Managing Director and Whole Time Director. The e-voting period concludes on November 17, 2026.
Senores Pharmaceuticals Management Change
Senores Pharmaceuticals re-appointed Swapnil Shah as MD and Chetan Shah as WTD for three-year terms. Both appointments are subject to shareholder approval via postal ballot.
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals submitted its Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2026, as required by SEBI regulation 76.
Senores Pharmaceuticals Annual General Meeting
Senores Pharmaceuticals held its 9th Annual General Meeting on September 25, 2026. Shareholders approved financial statements, director appointments, and the new Employee Stock Option Scheme 2026.
Senores Pharmaceuticals Price Movement Clarification
Senores Pharmaceuticals informed exchanges there is no undisclosed or price-sensitive information behind the volume spike. The company affirmed compliance with SEBI LODR disclosure obligations.
Other debt & borrowing announcements
All →Fusion CX Debt & Borrowing: ₹21.85 Cr
Fusion CX lent up to Rs.21.85 Crore (USD 2.3 million) to wholly owned subsidiary Fusion BPO Services. Terms: 8.5% interest, three-year tenure, unsecured.
- Value
- ₹21.85 Cr
- Execution
- 3 years from the date of disbursal
Fusion CX Debt & Borrowing
Fusion CX Limited executed an unsecured inter-corporate term loan at 8.5% p.a. for three years with its wholly owned subsidiary Fusion BPO Services Ltd, a related party. Amount is not stated in the filing.
- Execution
- 3 years from the date of disbursal
Spandana Sphoorty Financial Debt & Borrowing: ₹0.49 Cr
Spandana paid ₹0.49 Crore of quarterly interest on its secured NCDs on 27 October 2026. The coupon rate is 10.75% on a ₹50 Crore issue.
- Value
- ₹0.49 Cr
Mangalam Worldwide Debt & Borrowing: ₹1.14 Cr
Mangalam Worldwide paid Rs. 1.14 Crore interest on its NCDs (ISIN INE0JYY07026) on 28 October 2026, net of TDS. The company confirmed timely payment under Regulation 57.
- Value
- ₹1.14 Cr
Lloyds Metals & Energy Debt & Borrowing: ₹12,370 Cr
Lloyds Metals allotted 1,300 debt securities worth about ₹12,370 Crore on 29 October 2026. Three-year coupon is SOFR plus 450 bps, secured by Virtus Lloyds share pledges.
- Value
- ₹12,370 Cr
- Execution
- 3 years
Lloyds Metals & Energy Debt & Borrowing: ₹1,235 Cr
Lloyds Metals' committee approved terms for USD 130 million senior secured notes, about Rs.1,235 Crore. The notes mature in October 2029 at SOFR plus 450 bps.
- Value
- ₹1,235 Cr